Compass Therapeutics' (CMPX) "Buy" Rating Reaffirmed at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX - Free Report) in a research note issued to investors on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $32.00 price objective on the stock.

CMPX has been the subject of a number of other research reports. HC Wainwright reissued a "buy" rating and set a $10.00 target price on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Guggenheim initiated coverage on shares of Compass Therapeutics in a research report on Monday, February 24th. They issued a "buy" rating and a $12.00 price objective for the company. Piper Sandler initiated coverage on shares of Compass Therapeutics in a report on Wednesday, February 19th. They set an "overweight" rating and a $12.00 target price on the stock. Finally, Jefferies Financial Group increased their price target on Compass Therapeutics from $7.00 to $8.00 and gave the company a "buy" rating in a report on Monday, February 10th. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $11.63.

Compass Therapeutics Price Performance

NASDAQ:CMPX traded down $0.09 during trading hours on Tuesday, reaching $1.61. 1,908,897 shares of the company were exchanged, compared to its average volume of 806,124. Compass Therapeutics has a 52-week low of $0.77 and a 52-week high of $4.08. The stock has a 50 day simple moving average of $2.81 and a 200 day simple moving average of $2.11. The firm has a market cap of $221.94 million, a price-to-earnings ratio of -4.34 and a beta of 1.19.

Remove Ads

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). On average, analysts predict that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Compass Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Squarepoint Ops LLC acquired a new position in shares of Compass Therapeutics in the fourth quarter worth about $35,000. Tang Capital Management LLC lifted its stake in Compass Therapeutics by 225.4% during the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company's stock worth $8,555,000 after purchasing an additional 4,087,005 shares during the last quarter. ProShare Advisors LLC boosted its holdings in Compass Therapeutics by 49.0% in the fourth quarter. ProShare Advisors LLC now owns 28,722 shares of the company's stock worth $42,000 after purchasing an additional 9,451 shares during the period. MPM Bioimpact LLC increased its stake in Compass Therapeutics by 51.9% during the fourth quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company's stock valued at $12,423,000 after purchasing an additional 2,926,002 shares during the last quarter. Finally, Enavate Sciences GP LLC acquired a new stake in shares of Compass Therapeutics during the fourth quarter worth $11,293,000. Institutional investors and hedge funds own 68.43% of the company's stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.